Peter Gibbs, MBBS
Adding selective internal radiation therapy (SIRT) with Yttrium-90 (Y-90) resin microspheres to frontline FOLFOX-based chemotherapy improved liver-specific progression-free survival (PFS) by 7.9 months for patients with colorectal cancer (CRC) with liver-dominant metastases. However, the primary endpoint of improvement in PFS at all sites was not achieved, according to findings from the phase III SIRFLOX study presented at the 2015 ASCO Annual Meeting.
The rate of complete response (CR) in the liver was significantly improved with the addition of SIRT. In the microsphere arm the CR rate was 6.0% versus 1.9% without SIRT (P
"We did see some major changes in progression-free survival in the liver, and we did observe an improvement in the complete response rate,” Gibbs explained. "There was no difference in the number of patients undergoing hepatic resection between the two arms."
... to read the full story